Published in J Natl Cancer Inst on October 13, 2010
Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes. BMJ (2014) 4.75
Mortality after prostate cancer treatment with radical prostatectomy, external-beam radiation therapy, or brachytherapy in men without comorbidity. Eur Urol (2013) 3.41
Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Eur Urol (2012) 2.62
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood (2010) 1.67
Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database. Biol Blood Marrow Transplant (2015) 1.42
Choosing models for health care cost analyses: issues of nonlinearity and endogeneity. Health Serv Res (2012) 1.13
Methods in comparative effectiveness research. J Clin Oncol (2012) 1.12
Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer. Cancer (2014) 1.08
Reducing bias in the assessment of treatment effectiveness: androgen deprivation therapy for prostate cancer. Med Care (2012) 0.98
The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. J Natl Cancer Inst (2015) 0.89
Linking Medicare, Medicaid, and cancer registry data to study the burden of cancers in West Virginia. Medicare Medicaid Res Rev (2012) 0.87
Re: Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2011) 0.87
Comparing cancer care, outcomes, and costs across health systems: charting the course. J Natl Cancer Inst Monogr (2013) 0.86
What is the effect of area size when using local area practice style as an instrument? J Clin Epidemiol (2013) 0.82
Evaluating comparative effectiveness with observational data: endoscopic ultrasound and survival in pancreatic cancer. Cancer (2013) 0.81
Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. Cancer Invest (2011) 0.81
Using multiple types of studies in systematic reviews of health care interventions--a systematic review. PLoS One (2013) 0.81
Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer. Obstet Gynecol (2016) 0.80
Bias in estimating the causal hazard ratio when using two-stage instrumental variable methods. Stat Med (2015) 0.79
Healthcare Databases in Thailand and Japan: Potential Sources for Health Technology Assessment Research. PLoS One (2015) 0.78
The role of randomized controlled trials in evidence-based urology. World J Urol (2011) 0.76
Survival after partial breast brachytherapy in elderly patients with nonmetastatic breast cancer. Brachytherapy (2013) 0.76
Comparative Effectiveness of Minimally Invasive Hysterectomy for Endometrial Cancer. J Clin Oncol (2016) 0.75
ESTIMATING PERSON-CENTERED TREATMENT (PeT) EFFECTS USING INSTRUMENTAL VARIABLES: AN APPLICATION TO EVALUATING PROSTATE CANCER TREATMENTS. J Appl Econ (Chichester Engl) (2015) 0.75
Patterns of cancer screening, incidence and treatment disparities in China: protocol for a population-based study. BMJ Open (2016) 0.75
Prescription of extended-duration thromboprophylaxis after high-risk, abdominopelvic cancer surgery. Gynecol Oncol (2016) 0.75
Re: Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2011) 0.75
Comparative effectiveness research in gynecologic oncology. Cancer Treat Res (2015) 0.75
Treatment and Survival of Medicare Beneficiaries with Colorectal Cancer: A Comparative Analysis Between a Rural State Cancer Registry and National Data. Popul Health Manag (2016) 0.75
An approach to addressing selection bias in survival analysis. Stat Med (2014) 0.75
Treatment Effect Estimation Using Nonlinear Two-Stage Instrumental Variable Estimators: Another Cautionary Note. Health Serv Res (2016) 0.75
Nephron Sparing Surgery Has Better Oncologic Outcomes Than Extirpative Nephrectomy in T1a but Not in T1b or T2 Stage Renal Cell Carcinoma. Med Sci Monit (2017) 0.75
A systematic review of instrumental variable analyses using geographic region as an instrument. Cancer Epidemiol (2017) 0.75
Rural-Urban Differences in the Effect of Follow-Up Care on Postdischarge Outcomes. Health Serv Res (2016) 0.75
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med (2005) 16.35
Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst (2008) 8.62
Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics (1998) 8.48
Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA (2006) 8.16
A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol (2005) 7.31
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol (2005) 6.20
Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med (2008) 6.02
Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA (2008) 5.66
Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Econ (2007) 5.61
Outcomes of localized prostate cancer following conservative management. JAMA (2009) 5.57
The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics (1968) 5.54
A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol (2007) 4.81
Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer (2007) 3.92
Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol (2005) 3.76
Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases. Med Care (2007) 3.53
Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients. Med Care (2006) 3.08
Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol (1995) 2.41
Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol (2001) 2.37
Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey. Cancer (2007) 2.31
Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst (2001) 2.09
Limits of observational data in determining outcomes from cancer therapy. Cancer (2008) 1.97
Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev (2008) 1.95
Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol (2009) 1.73
Overview of the special supplement issue. Health Serv Res (2000) 1.72
Was breast conserving surgery underutilized for early stage breast cancer? Instrumental variables evidence for stage II patients from Iowa. Health Serv Res (2003) 1.72
Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. J Clin Epidemiol (2009) 1.56
13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort. J Urol (2007) 1.36
Use of instrumental variables in the presence of heterogeneity and self-selection: an application to treatments of breast cancer patients. Health Econ (2007) 1.34
An exploratory instrumental variable analysis of the outcomes of localized breast cancer treatments in a medicare population. Health Econ (2003) 1.34
Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med (2007) 1.26
Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects? Med Care (2007) 1.21
Changing patterns in competing causes of death in men with prostate cancer: a population based study. J Urol (2004) 1.18
Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer. Int J Radiat Oncol Biol Phys (2006) 1.14
Comparison of cancer diagnosis and treatment in Medicare fee-for-service and managed care plans. Med Care (2008) 1.07
Long-term survival probability in men with clinically localized prostate cancer treated either conservatively or with definitive treatment (radiotherapy or radical prostatectomy). Urology (2006) 1.05
Sensitivity of the hazard ratio to nonignorable treatment assignment in an observational study. Stat Med (2007) 1.02
Heterogeneity and the interpretation of treatment effect estimates from risk adjustment and instrumental variable methods. Med Care (2007) 1.02
Treating older men with prostate cancer: survival (or selection) of the fittest? JAMA (2006) 0.98
The instrumental variable method to study self-selection mechanism: a case of influenza vaccination. Value Health (2006) 0.95
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst (2011) 10.29
Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst (2002) 9.45
Prevalence of kidney stones in the United States. Eur Urol (2012) 9.42
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Long-term functional outcomes after treatment for localized prostate cancer. N Engl J Med (2013) 7.95
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol (2014) 6.62
Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst (2004) 5.84
Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst (2005) 5.10
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst (2008) 4.53
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer. J Natl Cancer Inst (2013) 3.81
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst (2012) 3.72
Ureteroenteric anastomotic strictures after radical cystectomy-does operative approach matter? J Urol (2012) 3.30
National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline. Ann Intern Med (2010) 3.24
Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst (2006) 3.19
Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev (2009) 3.04
Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA (2010) 2.93
Comparative effectiveness of shock wave lithotripsy and ureteroscopy for treating patients with kidney stones. JAMA Surg (2014) 2.89
Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int (2012) 2.88
Urologic diseases in America Project: analytical methods and principal findings. J Urol (2005) 2.87
Association between colonoscopy and colorectal cancer mortality in a US cohort according to site of cancer and colonoscopist specialty. J Clin Oncol (2012) 2.77
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol (2005) 2.72
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending? Arch Intern Med (2010) 2.59
A population-based assessment of specialty physician involvement in cancer clinical trials. J Natl Cancer Inst (2011) 2.48
Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer (2006) 2.42
Diffusion of surgical innovation among patients with kidney cancer. Cancer (2008) 2.38
The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care (2011) 2.38
Trends in stricture management among male Medicare beneficiaries: underuse of urethroplasty? Urology (2010) 2.37
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Immediate effects of the initial FDA notification on the use of surgical mesh for pelvic organ prolapse surgery in medicare beneficiaries. Neurourol Urodyn (2012) 2.35
Identifying cancer relapse using SEER-Medicare data. Med Care (2002) 2.28
Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population. Urology (2011) 2.26
What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer Epidemiol Biomarkers Prev (2011) 2.25
Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol (2007) 2.24
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
Productivity costs of cancer mortality in the United States: 2000-2020. J Natl Cancer Inst (2008) 2.23
Impact of cancer on health-related quality of life of older Americans. J Natl Cancer Inst (2009) 2.20
NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline. NIH Consens State Sci Statements (2010) 2.19
Use of radical cystectomy for patients with invasive bladder cancer. J Natl Cancer Inst (2010) 2.17
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol (2008) 2.16
Recruitment and follow-up of adolescent and young adult cancer survivors: the AYA HOPE Study. J Cancer Surviv (2011) 2.15
Access to information sources and treatment considerations among men with local stage prostate cancer. Urology (2009) 2.15
End-of-life care for lung cancer patients in the United States and Ontario. J Natl Cancer Inst (2011) 2.14
Comparability of segmented line regression models. Biometrics (2004) 2.12
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
Compliance with antibiotic prophylaxis in children with vesicoureteral reflux: results from a national pharmacy claims database. J Urol (2010) 2.05
The prevalence of urinary incontinence among community dwelling adult women: results from the National Health and Nutrition Examination Survey. J Urol (2006) 2.02
Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection. J Natl Cancer Inst (2006) 2.01
Physician roles in the cancer-related follow-up care of cancer survivors. Fam Med (2013) 2.00
Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer. J Gen Intern Med (2004) 1.97
Health related quality of life after radical cystectomy and urinary diversion for bladder cancer: a systematic review and critical analysis of the literature. J Urol (2005) 1.97
Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer (2009) 1.95
General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol (2003) 1.91
Renal and cardiovascular morbidity after partial or radical nephrectomy. Cancer (2008) 1.89
Recurrence of high-risk bladder cancer: a population-based analysis. Cancer (2013) 1.87
National trends in the use of partial nephrectomy: a rising tide that has not lifted all boats. J Urol (2012) 1.84
Care for the caregivers: a review of self-report instruments developed to measure the burden, needs, and quality of life of informal caregivers. J Pain Symptom Manage (2003) 1.84
Volume outcomes of cystectomy--is it the surgeon or the setting? J Urol (2012) 1.77
Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J Gen Intern Med (2011) 1.76
Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol (2004) 1.75
Variation in continence and potency by definition. J Urol (2003) 1.75
Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol (2007) 1.74
Quality of care in patients with bladder cancer: a case report? Cancer (2011) 1.73
Prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer. J Urol (2011) 1.72
Do patients consistently report comorbid conditions over time?: results from the prostate cancer outcomes study. Med Care (2005) 1.71
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology (2004) 1.71
Quality of surveillance for stage I testis cancer in the community. J Clin Oncol (2009) 1.69
Variations in reconstruction after radical cystectomy. Cancer (2006) 1.69
Medical oncologists' perceptions of financial incentives in cancer care. J Clin Oncol (2012) 1.69
Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation. J Urol (2004) 1.68
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer. Clin Cancer Res (2008) 1.68
Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol (2008) 1.66
Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Urology (2013) 1.66
Physicians' decision-making style and psychosocial outcomes among cancer survivors. Patient Educ Couns (2009) 1.65
Projecting the number of patients with colorectal carcinoma by phases of care in the US: 2000-2020. Cancer Causes Control (2006) 1.64
Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database. J Urol (2010) 1.64
Urinary diversion and morbidity after radical cystectomy for bladder cancer. Cancer (2010) 1.63
Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. Ann Intern Med (2013) 1.62
The demographic burden of urologic diseases in America. Urol Clin North Am (2009) 1.61
Health related quality of life for men treated for localized prostate cancer with long-term followup. J Urol (2010) 1.60
Cross-sectional and longitudinal comparisons of health-related quality of life between patients with prostate carcinoma and matched controls. Cancer (2004) 1.60
Invasive T1 bladder cancer: indications and rationale for radical cystectomy. BJU Int (2008) 1.59
Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int (2010) 1.57
Psychometric characteristics of a condition-specific, health-related quality-of-life survey: the FACT-Vanderbilt Cystectomy Index. Urology (2012) 1.56
Emergency department revisits for patients with kidney stones in California. Acad Emerg Med (2015) 1.56